TapImmune Inc. Stock Other OTC
Stocks
US8760333091
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Market Cap | 18.51M 16.26M 15.18M 13.93M 26.08M 1.77B 26.72M 180M 70.39M 877M 69.49M 67.98M 3.03B | P/E 2026 * |
-1.15x | P/E 2027 * | -1.1x |
|---|---|---|---|---|---|
| Enterprise Value | 18.51M 16.26M 15.18M 13.93M 26.08M 1.77B 26.72M 180M 70.39M 877M 69.49M 67.98M 3.03B | EV / Sales 2026 * |
6.54x | EV / Sales 2027 * | 0.92x |
| Free-Float |
94.51% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: TapImmune Inc.
| 21-08-20 | Wall Street hoger gesloten | |
| 21-08-20 | Wall Street koerst af op hoger slot | |
| 21-08-20 | Wall Street richting lagere opening |
| Manager | Title | Age | Since |
|---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 46 | 2023-04-30 |
| Chief Operating Officer | 36 | 2023-11-30 | |
Patricia Allison
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Juan Vera
BRD | Director/Board Member | 46 | 2018-10-16 |
Norman Eansor
CHM | Chairman | 65 | 2022-05-23 |
Steven Elms
BRD | Director/Board Member | 62 | 2019-08-05 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.61% | +7.16% | -0.93% | +13.91% | 47.88B | |
| -1.60% | -1.15% | +388.84% | +603.70% | 39.09B | |
| -0.98% | +2.28% | +7.02% | +45.34% | 36.75B | |
| +1.90% | +24.70% | +27.25% | +9.47% | 40.55B | |
| +1.47% | +5.82% | +5.76% | +43.52% | 27.96B | |
| -0.94% | +0.05% | - | - | 16.77B | |
| +2.44% | +10.76% | +30.59% | +129.56% | 15.94B | |
| +0.18% | -2.75% | +3.22% | +10.14% | 13.55B | |
| -1.14% | +6.52% | -3.80% | -29.33% | 13.81B | |
| Average | +0.44% | +4.61% | +57.24% | +103.29% | 28.03B | |
| Weighted average by Cap. | +0.61% | +4.92% | +72.85% | +124.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.83M 2.49M 2.32M 2.13M 3.99M 271M 4.09M 27.53M 10.77M 134M 10.63M 10.4M 464M | 20.09M 17.65M 16.47M 15.12M 28.3M 1.92B 29M 195M 76.4M 952M 75.41M 73.77M 3.29B |
| Net income | -19.36M -17.01M -15.88M -14.57M -27.28M -1.85B -27.95M -188M -73.64M -918M -72.69M -71.12M -3.17B | -19.89M -17.48M -16.32M -14.97M -28.03M -1.91B -28.72M -193M -75.66M -943M -74.68M -73.06M -3.26B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
